Abstract:Key PointsThree vascular endothelial growth-factor receptors (VEGFRs) regulate vascular-endothelial, haematopoietic and lymphatic-endothelial cell function during development and in the adult. Many of these processes require balanced VEGFR signalling, which involves more than one of the VEGFRs.VEGFR1 signalling seems to be dispensable for endothelial-cell function, but it is essential for the migration of haematopoietic cells. A soluble splice variant of VEGFR1, which lacks the intracellular domain, might function as a VEGF 'trap', and is implicated in preeclampsia during pregnancy. VEGFR1 signal transduction might positively or negatively regulate VEGFR2 activity.VEGFR2 is absolutely required for endothelial-cell development and survival of blood vessels. Tyrosine phosphorylation sites in VEGFR2 regulate kinase activity and binding of phospholipase C-γ, and the adaptor molecules TSAd, Shb and Sck. VEGFR2-blocking therapies are in use or are being tested for the treatment of human malignancies.VEGFR3 is required for cardiovascular development and lymphangiogenesis. Certain VEGF family members might induce formation of heterodimers, which involves VEGFR2 and VEGFR3, thereby regulating the phosphorylation of VEGFR3 and consequent signal transduction.Co-receptors (VEGF-binding molecules that might lack intrinsic catalytic function) such as heparan-sulphate proteoglycans and neuropilins are engaged in the VEGFR signalling complex in a manner that is guided by the VEGF isoform. Co-receptors modulate the duration and quality of VEGFR signalling by the formation of VEGF gradients and by stabilizing the signalling complex. Cell?cell and cell?matrix adhesion molecules that are regulated, for example, by blood flow, affect VEGFR signalling by allowing receptor activation in the absence of VEGF.The signal from an activated VEGFR is influenced by several factors (the particular VEGF isoform, the possibility of homodimerization or heterodimerization with other VEGFRs, co-receptors or adhesion molecules) in the local milieu.

Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1

Direct Evidence for Endothelial Vascular Endothelial Growth Factor Receptor-1 Function in Nitric Oxide-Mediated Angiogenesis

Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis

Biology and therapeutic targeting of vascular endothelial growth factor A

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

sFlt-1: A Double Regulator in Angiogenesis-related Diseases

Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

The biology of VEGF and its receptors

VEGFR1 signaling in retinal angiogenesis and microinflammation

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Mechanisms and regulation of endothelial VEGF receptor signalling

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

VEGF receptor signalling ? in control of vascular function

Tnfsf15 Inhibits Vasculogenesis by Regulating Relative Levels of Membrane-Bound and Soluble Isoforms of Vegf Receptor 1

VEGF in biological control

Vitronectin Regulation of Vascular Endothelial Growth Factor-Mediated Angiogenesis

Expression of Soluble Vascular Endothelial Growth Factor Receptor-2 and Its Effect on Proliferation of Vascular Endothelial Cells

VEGF and inhibitors of TGFβ type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression

Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells